Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.
The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.
H05B 3/26 - Heating elements having extended surface area substantially in a two-dimensional plane, e.g. plate-heater non-flexible heating conductor mounted on insulating base
H05B 3/06 - Heater elements structurally combined with coupling elements or with holders
H05B 3/16 - Heating elements characterised by the composition or nature of the materials or by the arrangement of the conductor the conductor being mounted on an insulating base
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Pharmaceutical compositions comprising 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and one or more pharmaceutically acceptable carriers or excipients are described, as well as uses thereof as a medicament.
This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the a invention relates to formulations and uses of the same as a medicament.
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.
This invention relates to a nasal delivery device comprising 5-methoxy-N,N-dimethyltryptamine (5-MeO- DMT) pharmaceutical compositions or formulations, more particularly intranasal pharmaceutical compositions or formulations of pharmaceutically acceptable salts of 5-MeO-DMT, and methods of administration and treatment using the same.
This invention relates to 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) pharmaceutical compositions, more particularly intranasal pharmaceutical compositions of pharmaceutically acceptable salts of 5-MeO-DMT, and methods of administration and treatment using the same.
A pharmaceutically acceptable composition may include 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). A method of treating a subject may include administering the composition to the subject. The method may treat or prevent depression in the subject. Administration of the composition to the subject may produce in the subject a blood plasma Cmax of about 4 ng/mL to about 39 ng/mL.
The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.
This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
13.
Pharmaceutically acceptable salts and compositions thereof
Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
This invention relates to pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine. In particular, though not exclusively, the invention relates to compositions/formulations and uses of the same as a medicament.
This invention relates to pharmaceutically acceptable ergoline and tryptamine-based compounds (e.g. analogues, prodrugs and salts thereof). In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament, alone or in combination with additional pharmaceutically acceptable compounds.
An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of:
peaks in an XRPD diffractogram;
an endothermic event in a DSC thermograph;
an onset of decomposition in a TGA thermograph; and
a DVS isotherm profile.
A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals for the treatment of psychiatric and neurological conditions; medical preparations for the treatment of psychiatric and neurological conditions, namely, depression, major depressive disorder, treatment-resistant depression, anxiety, substance misuse disorders, alcohol use disorder, bipolar disorder, post-traumatic stress disorder, and eating disorders Scientific services, namely, development of pharmaceuticals for the treatment of psychiatric and neurological conditions; scientific research services for others in the field of medicinal preparations for the treatment of psychiatric and neurological conditions such as depression, major depressive disorder, treatment-resistant depression, anxiety, substance misuse disorders, alcohol use disorder, bipolar disorder, post-traumatic stress disorder, and eating disorders; providing information about medical and scientific research, and development in the field of medicinal preparations for the treatment of psychiatric and neurological conditions, such as depression, major depressive disorder, treatment-resistant depression, anxiety, substance misuse disorders, alcohol use disorder, bipolar disorder, post-traumatic stress disorder, and eating disorders; providing scientific advice and consultancy services relating to the research and development of medicinal preparations for the treatment of psychiatric and neurological conditions Providing medical information relating to the use of medicinal preparations for the treatment of psychiatric and neurological conditions, such as depression, major depressive disorder, treatment-resistant depression, anxiety, substance misuse disorders, alcohol use disorder, bipolar disorder, post-traumatic stress disorder, and eating disorders; providing medical advisory and consultancy services relating to the treatment of psychiatric and neurological conditions, and the use of medicinal preparations for the treatment of psychiatric and neurological conditions
19.
Pharmaceutically acceptable salts and compositions thereof
Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
A method of synthesizing the benzoate salt of 5-MeO-DMT comprising the step of treating the hydrochloride salt of 5-MeO-DMT with a base, prior to the addition of benzoic acid.
A method of producing polymorph A' of psilocybin, the method comprising passing a flow of an inert gas under reduced pressure over a hydrated form of psilocybin.
This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
A61K 9/00 - Medicinal preparations characterised by special physical form
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.
A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.
A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals; pharmaceutical and medical preparations;
psychedelics; psychedelic compounds; psilocybin; psychedelic
tryptamines; 5-MeO-DMT; psychedelic ergolines; LSD;
non-hallucinogenic tryptamines; non-hallucinogenic
ergolines; all the aforesaid for pharmaceutical and medical
purposes. Scientific services; scientific research services; research
and development in relation to psychedelic compounds;
information, advisory, and consultancy services relating to
all of the aforesaid.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals; pharmaceutical and medical preparations;
psychedelics; psychedelic compounds; psilocybin; psychedelic
tryptamines; 5-MeO-DMT; psychedelic ergolines; LSD;
non-hallucinogenic tryptamines; non-hallucinogenic
ergolines; all the aforesaid for pharmaceutical and medical
purposes. Scientific services; scientific research services; research
and development in relation to psychedelic compounds;
information, advisory, and consultancy services relating to
all of the aforesaid.
32.
PHARMACEUTICAL COMPOSITION COMPRISING PSILOCYBIN OR ITS POLYMORPHS
A composition for use in a method of treatment of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) or short-lasting neuralgiform headaches with cranial autonomic symptoms (SUNA), wherein the composition comprises a pharmaceutically effective amount of psilocybin, psilocin or a prodrug thereof, wherein the psilocybin, psilocin or a prodrug thereof, has been synthesised, or has been isolated from a naturally occurring substance or product.
A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
An intranasal composition comprising a dosage amount of 50-150mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.
